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Abstract
Vaccination against inﬂuenza is currently recommended for patients with rheumatoid arthritis (RA). The safety and efﬁcacyof
vaccination in patients suffering from rheumatic diseases is still a matter of debate. This review summarizes the studies
performed on the safety and immunogenicity of inﬂuenza vaccination in patients with RA as well as the rheumatic
complications of the vaccine in otherwise healthy persons. Several trials have shown that the vaccine induces an adequate
humoral response and does not induce clinical exacerbation of RA. Rheumatic complications (mainly vasculitis) following
inﬂuenza vaccination in the general population are scarce.
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Yearly inﬂuenza vaccination is currently re-
commended for patients with rheumatoid arthritis
(RA) (Center for Disease Control and Prevention
2002). Despite this speciﬁc recommendation, the
uptake of inﬂuenza vaccination in patients with RA is
low (Bridges et al. 2003). The principal reason seems
not to be a lack of awareness of the need of vaccination
by the patient, but the fact that they have not been
offered it (Bridges et al. 2003).
This reluctance to vaccinate RA patients is based on
sporadic case reports on the onset or exacerbation of
RA following vaccination with inﬂuenza, tetanus,
hepatitis and other vaccines (Older et al. 1999,
Maillefert et al. 1999). However, the eventual capacity
of inﬂuenza vaccination to induce a signiﬁcant clinical
ﬂare of RA is still debated. One study reported post
vaccination ﬂare in 6 out of 17 patients (Herron et al.
1979) while no ﬂares were reported in further studies
(Arnold and Hochberg 1989, Turner Strokesluenza
et al. 1988, Chalmers et al. 1994).
On the other hand, there is uncertainty concerning
the immunogenicity of vaccination in immunocom-
promised patients such as RA patients.
The present report summarizes the current knowl-
edge on the efﬁcacy and safety of vaccination against
inﬂuenza in RA patients.
Trials on the effect of vaccination against
inﬂuenza in RA patients
Adult RA patients
The ﬁrst study on the safety and efﬁcacy of inﬂuenza
vaccination was reported in 1979 (Herron et al. 1979).
The subjects participating in this study were 62
patients with systemic lupus erythematosus (SLE),
RA, degenerative joint disease and 32 healthy
volunteers. Flare-ups of rheumatic disease following
immunization were infrequent and usually minor.
Seroconversion to A/New Jersey/76 developed in
62–87% of all individuals and to A/Victoria/75 in
62–69%. Administration of this vaccine induced an
adequate antibody response in both healthy and
rheumatic patients (Herron et al. 1979).
Chalmers et al. have addressed the issue of
immunogenicity and safety in 126 RA patients
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vaccination with inﬂuenza vaccine within 24 months
who were receiving usual therapy for RA (2) those
receiving usual therapy without prior vaccine and (3)
those receiving immunosuppressive medication or
prednisone .7.5mg/day. Within each group, patients
were randomized to receive vaccine or placebo.
During 1-month follow-up period, adverse reactions
occurred with equal frequency among patients with
RA and healthy controls. Similar signiﬁcant increases
in titers to the vaccine were seen in all groups of
patients with arthritis and in the controls (Chalmers
et al. 1994).
Our group has studied the effect of inﬂuenza
vaccination in 82 RA patients and 30 healthy controls
using a split-virion inactivated vaccine containing
15mcg hemagglutinin (HA)/dose of each of B/Hong
Kong/330 (hk), A/Panama/2007/99 (pan) and A/New
Caledonian /20/90 (nc) (Fomin et al. 2006). Six weeks
after vaccination, a signiﬁcant increase in geometric
mean titer of hemaglutination inhibition antibodiesfor
each antigen was observed in both groups, the increase
being signiﬁcantly higher in the healthy group for hk
(p ¼ 0.004). The percentage of responders was lower
in RA patients in comparison with healthy controls
achieving statistical signiﬁcance for hk. Parameters of
disease activity such as number of tender and swollen
joints, morning stiffness, evaluation of pain, health
assessment questionnaire, ESR and CRP remained
unchanged. Our study clearly showed that inﬂuenza
virus vaccine generated a good humoral response in
RA patients, although lower than in healthy controls
(Fomin et al. 2006).
Children with chronic arthritis
Malleson et al. have reported their experience with
inﬂuenza vaccination using an inactivated split virus
vaccine prepared for the 1991/1992 season in a
prospective open study of 34 children with chronic
arthritis and 11 healthy control children. Tenderness
and/or redness at the injection site occurred equally in
patients and controls. Malaise/nausea occurred in 12
patients and three controls but patients had more
symptomatic days than controls. No signiﬁcant
worsening of indices of disease activity such as
morning stiffness, pain, joint count and ESR were
observed. At least 95% of patients developed
presumably protective levels of antibodies. Preimmu-
nization titers, seroresponse rates and ﬁnal titers were
the same between patients and controls (Malleson
et al. 1993).
A subsequent report published in 2001 has
conﬁrmed the safety and efﬁcacy of inﬂuenza
vaccination in 70 children with chronic rheumatic
diseases (Juvenile RA 49, SLE 11, other 10) aged 4–
17 years and ﬁve healthy siblings who received a split
type inﬂuenza vaccine for the 1999–2000 winter
season. Five out of 70 patients reported local (three
patients) or systemic (two patients) reactions and 1/5
siblings local reaction. Nine more patients reported
mild upper respiratory tract symptoms 1–4 weeks
post-vaccination. No patient was found to fulﬁll
criteria for deterioration or ﬂare of the underlying
disease.
At completion of vaccination 97% of patients
developed protective HI titers to A/Beijing, 100%
to A/Sydney and 80% to B/Beijing (Kanakoudi-
Tsakalidou et al. 2001).
The effect of immunosuppressive drugs on the
efﬁcacy of inﬂuenza vaccination in RA patients
Various studies have addressed the effect of gluco-
corticoids on the immunogenicity of the vaccine
(Malleson et al. 1993, Chalmers et al. 1994,
Kanakoudi-Tsakalidou et al. 2001). They all showed
that glucocorticoids did not signiﬁcantly affect the
development of protective antibodies (Malleson et al.
1993, Chalmers et al. 1994, Kanakoudi-Tsakalidou
et al. 2001). The same was demonstrated for gold,
imuran and methotrexate (Chalmers et al. 1994,
Fomin et al. 2006).
Our group has found that the use of inﬂiximab did
n o ts e e mt oi n ﬂ u e n c et h eh u m o r a lr e s p o n s et o
inﬂuenza vaccine.
Thus, it seems that the use of immunosuppressive
drugs,atthedosageusedtotreatpatientswithRA,does
not affect the efﬁcacy of vaccination against inﬂuenza.
Rheumatic complications of inﬂuenza
vaccination
Vasculitis is by far the most common rheumatic
complication following inﬂuenza vaccination.
Although this association is far from being new
(Wharton and Pietroni 1974), it is of importance in
that small, medium or large vessels can apparently be
involved (Ghose et al. 1976, Blumberg et al. 1980,
Kelsall et al. 1997, Perez et al. 2000, Finsterer et al.
2001, Iyngkaran et al. 2003). Blumberg has described
two patients who experienced small-vessel vasculitic
syndromes after inﬂuenza immunization (Blumberg
et al. 1980). Their illnesses were characterized by
fever, arthralgias and myalgias; uveitis and optic
neuritis occurred in one patient, while the other had
palpable purpura, which histologically was proved to
be a cutaneous necrotizing venulitis. Kelsall et al.
(1997) reported a case of microscopic polyangiitis that
developed after inﬂuenza vaccination, with increased
titers of anti-inﬂuenza A antibody in synovial ﬂuid.
Their review of the literature found 16 cases of
vasculitis that occurred after IV, which were reclassi-
ﬁed according to the Chapel Hill diagnostic criteria as
follows: microscopic polyangiitis, Churg-Strauss syn-
drome, cutaneous leukocytoclastic vasculitis, and
O. Elkayam 350Henoch-Scho ¨nlein purpura. Giant cell arteritis occur-
ring shortly after inﬂuenza vaccination has been
described in three cases (Ghose et al. 1976, Perez et al.
2000, Finsterer et al. 2001) further expanding the
spectrum of vasculitis induced by vaccination. A single
case of rheumatoid vasculitis triggered by inﬂuenza
vaccination in a patient suffering from RA has been
reported (Iyngkaran et al. 2003).
Sporadic cases of arthritis, including polyarthritis
(Thurairajan et al. 1997) and reactive arthritis (Biasi
et al. 1994) complete the repertoire of rheumatic
complications of inﬂuenza vaccination.
Conclusion
The effect of vaccination against inﬂuenza in RA has
been investigated in several trials. They all conclude
that the vaccine is safe, does not induce an
exacerbation of the disease and achieves an immuno-
genic response similar to the one observed in healthy
subjects, although a trend toward a lower response has
been reported in some of the studies. The effect of
glucocorticoids and disease-modifying drugs, includ-
ing inﬂiximab, on the humoral response seems to be
negligible. Vaccination against inﬂuenza has been
associated with sporadic cases of vasculitis and
arthritis. Inﬂuenzavaccination mayhave the capability
to induce rheumatic complications in predisposed
patients. However, the scarcity of the reports in
comparison with the huge number of recipients of the
ﬂu vaccine all over the years is reassuring.
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